Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Detalles Bibliográficos
Autores principales: Chang, Vicky C., Khan, Ali A., Huang, Wen-Yi, Katki, Hormuzd A., Purdue, Mark P., Landgren, Ola, Hofmann, Jonathan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975932/
https://www.ncbi.nlm.nih.gov/pubmed/35365600
http://dx.doi.org/10.1038/s41408-022-00642-4
_version_ 1784680464671309824
author Chang, Vicky C.
Khan, Ali A.
Huang, Wen-Yi
Katki, Hormuzd A.
Purdue, Mark P.
Landgren, Ola
Hofmann, Jonathan N.
author_facet Chang, Vicky C.
Khan, Ali A.
Huang, Wen-Yi
Katki, Hormuzd A.
Purdue, Mark P.
Landgren, Ola
Hofmann, Jonathan N.
author_sort Chang, Vicky C.
collection PubMed
description
format Online
Article
Text
id pubmed-8975932
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89759322022-04-20 Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Chang, Vicky C. Khan, Ali A. Huang, Wen-Yi Katki, Hormuzd A. Purdue, Mark P. Landgren, Ola Hofmann, Jonathan N. Blood Cancer J Correspondence Nature Publishing Group UK 2022-04-01 /pmc/articles/PMC8975932/ /pubmed/35365600 http://dx.doi.org/10.1038/s41408-022-00642-4 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Chang, Vicky C.
Khan, Ali A.
Huang, Wen-Yi
Katki, Hormuzd A.
Purdue, Mark P.
Landgren, Ola
Hofmann, Jonathan N.
Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
title Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
title_full Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
title_fullStr Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
title_full_unstemmed Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
title_short Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
title_sort body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: results from the prostate, lung, colorectal and ovarian cancer screening trial
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975932/
https://www.ncbi.nlm.nih.gov/pubmed/35365600
http://dx.doi.org/10.1038/s41408-022-00642-4
work_keys_str_mv AT changvickyc bodymassindexandriskofprogressionfrommonoclonalgammopathyofundeterminedsignificancetomultiplemyelomaresultsfromtheprostatelungcolorectalandovariancancerscreeningtrial
AT khanalia bodymassindexandriskofprogressionfrommonoclonalgammopathyofundeterminedsignificancetomultiplemyelomaresultsfromtheprostatelungcolorectalandovariancancerscreeningtrial
AT huangwenyi bodymassindexandriskofprogressionfrommonoclonalgammopathyofundeterminedsignificancetomultiplemyelomaresultsfromtheprostatelungcolorectalandovariancancerscreeningtrial
AT katkihormuzda bodymassindexandriskofprogressionfrommonoclonalgammopathyofundeterminedsignificancetomultiplemyelomaresultsfromtheprostatelungcolorectalandovariancancerscreeningtrial
AT purduemarkp bodymassindexandriskofprogressionfrommonoclonalgammopathyofundeterminedsignificancetomultiplemyelomaresultsfromtheprostatelungcolorectalandovariancancerscreeningtrial
AT landgrenola bodymassindexandriskofprogressionfrommonoclonalgammopathyofundeterminedsignificancetomultiplemyelomaresultsfromtheprostatelungcolorectalandovariancancerscreeningtrial
AT hofmannjonathann bodymassindexandriskofprogressionfrommonoclonalgammopathyofundeterminedsignificancetomultiplemyelomaresultsfromtheprostatelungcolorectalandovariancancerscreeningtrial

Ejemplares similares